| DESCRIPTION | - ALTSCHUL et al., J. Mol. Bio., (19900000), vol. 215, pages 403 - 410 | - |
| DESCRIPTION | - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402 | - |
| DESCRIPTION | - AMERI A; KURACHI S; SUEISHI K; KUWAHARA M; KURACHI K, "Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX", Blood, (20030301), vol. 101, no. 5, pages 1871 - 3 | - |
| DESCRIPTION | - ANSON DS; CHOO KH; REES DJ; GIANNELLI F; GOULD K; HUDDLESTON JA; BROWNLEE GG, "The gene structure of human anti-haemophilic factor IX", The EMBO Journal, (19840000), vol. 3, pages 1053 - 1060, XP000872222 | - |
| DESCRIPTION | - ANSON DS; CHOO KH; REES DJ; GIANNELLI F; GOULD K; HUDDLESTON JA; BROWNLEE GG, "The gene structure of human anti-hemophilic factor IX", The EMBO Journal, (19840000), vol. 3, pages 1053 - 1060, XP000872222 | - |
| DESCRIPTION | - BON et al., Semin Hematol., (19980000), vol. 35, no. 2, pages 11 - 17 | - |
| DESCRIPTION | - BOWIE et al., Science, (19900000), vol. 247, pages 1306 - 1310 | - |
| DESCRIPTION | - CHANG JL; JIN JP; LOLLAR P et al., "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", J Biol Chem, (19980000), vol. 273, pages 12089 - 12094 | - |
| DESCRIPTION | - CHANG JL; JIN JP; LOLLAR P et al., "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", J. Biol. Chem., (19980000), vol. 273, pages 12089 - 12094 | - |
| DESCRIPTION | - CHEUNG et al., J. Biol. Chem., (19920000), vol. 267, no. 29, pages 20529 - 20531 | - |
| DESCRIPTION | - DEVEREUX, Nucleic Acid Research, (19840000), vol. 12, page 387 | - |
| DESCRIPTION | - FRIEDLER et al., J. Biol Chem., (20000000), vol. 275, pages 23783 - 23789 | - |
| DESCRIPTION | - "GenBank", Database accession no. K02402 | - |
| DESCRIPTION | - "Gene bank", Database accession no. K02402 | - |
| DESCRIPTION | - GIANNELLI et al., "Hemophilia B: Database of point mutations and short additions and deletions", Nucleic Acids Research, (19900000), vol. 18, pages 4053 - 9 | - |
| DESCRIPTION | - GUI et al., Blood, (20020000), vol. 100, no. 1, pages 153 - 158 | - |
| DESCRIPTION | - KARLIN; ALTSCHUL, Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 5873 - 5877 | - |
| DESCRIPTION | - KHALIZZADEH et al., J. Ind. Microbiol. Biotechnol., (20040000), vol. 31, no. 2, pages 63 - 69 | - |
| DESCRIPTION | - LIM et al., J. Biol Chem., (19900000), vol. 265, no. 1, pages 144 - 150 | - |
| DESCRIPTION | - LOWE GDO, "Factor IX and thrombosis", British Journal of Haematology, (20010000), vol. 115, pages 507 - 513 | - |
| DESCRIPTION | - MAYFIELD et al., PNAS, (20030000), vol. 100, pages 438 - 442 | - |
| DESCRIPTION | - "Methods in Molecular Medicine, Vol 31: Hemostasis and Thrombosis Protocols", PETER GREEN, Hemophilia B mutational analysis, Humana Press Inc., vol. 31 | - |
| DESCRIPTION | - MUNETA et al., J. Vet. Med. Sci., (20030000), vol. 65, no. 2, pages 219 - 23 | - |
| DESCRIPTION | - MURPHY SL; HIGH KA, "Gene therapy for haemophilia", Br J Haematol., (20080300), vol. 140, no. 5, pages 479 - 87 | - |
| DESCRIPTION | - PALMER et al., Blood, (19890000), vol. 73, pages 483 - 445 | - |
| DESCRIPTION | - PHAM et al., Biotechnol. Bioeng., (20030000), vol. 84, pages 332 - 42 | - |
| DESCRIPTION | - PLATIS et al., Protein Exp. Purif., (20030000), vol. 31, no. 2, pages 222 - 30 | - |
| DESCRIPTION | - Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 2264 - 2268 | - |
| DESCRIPTION | - SCHUETTRUMPF et al., Blood, (20050000), vol. 105, no. 6, pages 2316 - 2323 | - |
| DESCRIPTION | - SKOKO et al., Biotechnol. Appl. Biochem., (20030000), vol. 38, pages 257 - 65 | - |
| DESCRIPTION | - TOOMEY JR; VALOCIK RE; KOSTER PF; GABRIEL MA; MCVEY M; HART TK; OHLSTEIN EH; PARSONS AA; BARONE FC, "Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke", Stroke, (20020200), vol. 33, no. 2, pages 578 - 85 | - |
| DESCRIPTION | - WAHIJ et al., J. Biol. Chem., vol. 280, no. 36, pages 31603 - 31607 | - |
| DESCRIPTION | - YAO et al., PNAS, (19910000), vol. 88, pages 8101 - 8105 | - |
| DESCRIPTION | - YOSHITAKE S; SCHACH BG; FOSTER DC et al., "Nucleotide Sequence of thr Gene for Human Factor IX (Antihemophilic Factor B", Biochemistry, (19850000), vol. 24, pages 3736 - 3750, XP001318488 | - |
| DESCRIPTION | - KURACHI K; DAVIE EW, "Isolation and characterization of a cDNA coding for human factor IX", Proc Natl Acad Sci USA, (19820000), vol. 79, doi:doi:10.1073/pnas.79.21.6461, pages 6461 - 6464, XP002135656 | |
| DESCRIPTION | - KUNKEL TA, "Rapid and efficient site-specific mutagenesis without phenotypic selection", Proc Natl Acad Sci USA, (19850000), vol. 82, doi:doi:10.1073/pnas.82.2.488, pages 488 - 492, XP002052322 | |
| DESCRIPTION | - KUNKEL TA, "Rapid and efficient site-specific mutagenesis without phenotypic selection", Proc Natl Acad Sci, USA, (19850000), vol. 82, doi:doi:10.1073/pnas.82.2.488, pages 488 - 492, XP002052322 | |
| OPPOSITION | - Anonymous, "A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)", Clinical Study NCT03861273, (20231101), pages 1 - 41, XP093182322 | - |
| OPPOSITION | - Anonymous, "BeneFix® Coagulation Factor IX (Recombinant)", Wyeth - Product Label, (20060801), Wyeth - Product Label , (20240222), XP093133928 | - |
| OPPOSITION | - Anonymous , "Human coagulation factor IX gene, complete cds", EBI/EMBL, (19860128), Database accession no. K02402, URL: EBI, XP093133906 | - |
| OPPOSITION | - Branden Carl, John Tooze, "The Building Blocks ", Introduction to Protein Structure - Second Edition, (19990101), pages 3 - 34, ISBN 978-0-8153-2305-1, XP093133882 | - |
| OPPOSITION | - Brunetti-Pierri Nicola, "Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Safety and Efcacy of Helper-Dependent Adenoviral Vectors (HDAd) for Hemophilia B Gene Therapy", Molecular Therapy, (20080501), vol. 16, no. 1, page S152, XP093207978 | - |
| OPPOSITION | - Catherine Manno et al., "Successful transduction of liver hemophilia by AAV-Factor IX and limitations imposed by the host immune response", Nature medicine, (20063), vol. 12, page 3, XP002578131 | - |
| OPPOSITION | - Graham J B, Lubahn D B, Lord S T, Kirshtein J, Nilsson I M, Wallmark A, Ljung R, Frazier L D, Ware J L, Lin S W, "The Malmö polymorphism of coagulation factor IX, an immunologic polymorphism due to dimorphism of residue 148 that is in linkage disequilibrium with two other F.IX polymorphisms", The American Journal of Human Genetics, American society of human genetics , Chicago , IL, US, US , (19880401), vol. 42, no. 4, ISSN 0002-9297, pages 573 - 580, XP093133889 | - |
| OPPOSITION | - "Human coagulation factor IX gene, complete cds", Nucleotide, (19960430), Database accession no. K02402, XP093182316 | - |
| OPPOSITION | - Kay Mark A, Manno Catherine S, Ragni Margaret V, Larson Peter J, Couto Linda B, Mcclelland Alan, Glader Bertil, Chew Amy J, Tai Shing Jen, Herzog Roland W, Arruda Valder, Johnson Fred, Scallan Ciaran, Skarsgard Erik, Flake Alan W, High Katherine A, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector", nature genetics, (20000301), vol. 24, pages 257 - 261, XP093133890 | - |
| OPPOSITION | - Lin Chia-Ni et al, "Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model", Blood, American Society of Hematology, US, US , (20081209), vol. 112, no. 11, ISSN 0006-4971, page 706, XP009133463 | - |
| OPPOSITION | - Michael Blaese R, Anderson W French, Culver Kenneth, "Gene therapy", What is biotechnology, (20180101), pages 1 - 12, What is biotechnology, URL: https://www.whatisbiotechnology.org/index.php/science/summary/gene-therapy/, (20240222), XP093133887 | - |
| OPPOSITION | - Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Castaman G, Sawyer E K, Leebeek F Wg, "Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B", Res Pract Thromb Haemost, (20210101), vol. 5, no. suppl.2, XP093182330 | - |
| OPPOSITION | - Nelson David L., Cox Michael M., Principles of Biochemistry, 5th ed., (20080101), page 73, XP093182343 | - |
| OPPOSITION | - Pfizer, "FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec", Press Release, (20230627), Press Release, URL: https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-pfizers-application-hemophilia-b-gene-therapy, XP093182337 | - |
| OPPOSITION | - Pfizer, "Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate", Press Release, (20221229), Press Release, URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study, XP093182321 | - |
| OPPOSITION | - Shen Yuqiao, Leonard Post, David M. Knipe, Peter M. Howley, "16. Viral Vectors and Their Applications", Fields VIROLOGY FIFTH EDITION, Wolters Kluwer, (20070101), pages 539 - 564, XP093133899 | - |
| OPPOSITION | - Shinji Yoshitake; Barbara G. Schach; Donald C. Foster; Earl W. Davie; Kotoku Kurachi, "Nucleotide Sequence of the Gene for Human Factor IX (Antihemophilic Factor B)", Biochemistry, (19850701), vol. 24, no. 14, ISSN 0006-2960, pages 3736 - 3750, XP001318488 | - |
| OPPOSITION | - Stefan Kofler et al., "Crystallographically mapped ligand binding differs in high and low IgE binding isoforms of birch pollen allergen Bet V 1", Journal of Molecular Biology, (20129), vol. 422, page 1, XP055938808 | - |
| OPPOSITION | - Stryer Lubert, "Molecular Design of Life. Protein Structure and function", Biochemistry. 4th Ed., W. H. Freeman and Company, (20000101), pages 1 - 144, XP093133884 | - |
| OPPOSITION | - Tormene Simioni P., G. Tognin, S Gavasso, C. Bulato, N. Finn, J, Spiezia, L. Radu, C. Arruda, V., "PL-TU-004 Evidence of the first X-linked thrombophilia due to a novel mutation in clotting factor IX gene resulting in hyperfunctional fix: factor IX arginine 338 leucine (factor IX padua)", Internationl Society on Thrombosis and Haemostasis, (20090401), vol. 7, no. (Suppl. 2, page 2, XP093133893 | - |
| OPPOSITION | - Wallmarka Anders, Kunket Glenna, Mouhuc Hassan, Boscod John, Ljung Rolf, Nilsson Inga Marie, Grahamb John B,, "Population Genetics of the Malmo Polymorphism of Coagulation Factor IX", Human Heredity, (19910101), vol. 41, pages 391 - 396, XP093133888 | - |
| OPPOSITION | - Anson D.S., Choo K.H., Rees D.J., Giannelli F., Gould K., Huddleston J.A., Brownlee G.G., "The gene structure of human anti-haemophilic factor IX.", The EMBO journal / European Molecular Biology Organization, IRL Press, Oxford, Oxford , (19840501), vol. 3, no. 5, doi:10.1002/j.1460-2075.1984.tb01926.x, ISSN 0261-4189, pages 1053 - 1060, XP093133881 | |
| OPPOSITION | - POMMIÉ CHRISTELLE ET AL, "IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties.", JOURNAL OF MOLECULAR RECOGNITION., HEYDEN & SON LTD., LONDON., GB, GB , (20040101), vol. 17, no. 1, doi:10.1002/JMR.647, ISSN 0952-3499, pages 17 - 32, XP002516734 | |
| OPPOSITION | - Lu H; Chen L; Wang H; Wu Z; Wu X; Wang X; Wang H; Lu D; Qiu X; Xue J, "Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX.", SCIENCE IN CHINA. SERIE C: LIFE SCIENCE, GORDON AND BREACH, AMSTERDAM, NL, NL , (20011201), vol. 44, no. 6, doi:10.1007/BF02879352, ISSN 1006-9305, pages 585 - 592, XP009114604 | |
| OPPOSITION | - YAN JING-BIN ET AL, "Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity", Biochemical Genetics, Springer US, New York, New York, (20060801), vol. 44, no. 7-8, doi:10.1007/s10528-006-9034-1, ISSN 0006-2928, pages 349 - 360, XP002523380 | |
| OPPOSITION | - KYTE J., DOOLITTLE R. F., "A SIMPLE METHOD FOR DISPLAYING THE HYDROPATHIC CHARACTER OF A PROTEIN.", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom , (19820505), vol. 157., no. 01., doi:10.1016/0022-2836(82)90515-0, ISSN 0022-2836, pages 105 - 132., XP000609503 | |
| OPPOSITION | - Flotte S R, Berns Kenneth I, "chapter 1. Adeno-associated viral vectors for gene therapy", Adeno-associated viral vectors for gene therapy, Elsevier, (20050101), pages 1 - 82, doi:10.1016/80075-7535(05)31001-1, XP093133897 | |
| OPPOSITION | - Aucoin, M.G. Perrier, M. Kamen, A.A., "Critical assessment of current adeno-associated viral vector production and quantification methods", BIOTECHNOLOGY ADVANCES., ELSEVIER PUBLISHING, BARKING., GB, GB , (20071123), vol. 26, no. 1, doi:10.1016/j.biotechadv.2007.09.001, ISSN 0734-9750, pages 73 - 88, XP022360246 | |
| OPPOSITION | - Thierry Vandendriessche, Marinee K. Chuah, "Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy", Molecular Therapy, Elsevier Inc., US, US , (20180101), vol. 26, no. 1, doi:10.1016/j.ymthe.2017.12.007, ISSN 1525-0016, pages 14 - 16, XP055671234 | |
| OPPOSITION | - Xiao Xiao, Makrides S C, "Virus-based vectors for gene expression in mammalian cells: Adeno-associated virus", Gene Transfer and Expression in Mammalian Cells, Elsevier, (20030101), vol. 38, doi:10.1016/S0167-7306(03)38006-8, ISSN 0167-7306, ISBN 978-0-444-51371-7, pages 93 - 108, XP093133891 | |
| OPPOSITION | - HERZOG R W,ET AL, "Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.", Nature Medicine, Nature Publishing Group US, New York, New York, (19990101), vol. 5, no. 1, doi:10.1038/4743, ISSN 1078-8956, pages 56 - 63, XP002242060 | |
| OPPOSITION | - Kuzmin Dmitry A.; Shutova Maria V.; Johnston Natalie R.; Smith Owen P.; Fedorin Vasily V.; Kukushkin Yury S.; van der Loo Johannes C.M.; Johnstone Elaine C., "The clinical landscape for AAV gene therapies", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (19000101), vol. 20, no. 3, doi:10.1038/d41573-021-00017-7, ISSN 1474-1776, pages 173 - 174, XP037400659 | |
| OPPOSITION | - Hasbrouck N C; High K A, "AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects", Gene Therapy, Nature Publishing Group, London, GB, GB , (20080424), vol. 15, no. 11, doi:10.1038/gt.2008.71, ISSN 0969-7128, pages 870 - 875, XP037771869 | |
| OPPOSITION | - SNYDER R O, ET AL., "PERSISTENT AND THERAPEUTIC CONCENTRATIONS OF HUMAN FACTOR IX IN MICE AFTER HEPATIC GENE TRANSFER OF RECOMBINANT AAV VECTORS", Nature Genetics, Nature Publishing Group US, New York, New York, (19970716), vol. 16, doi:10.1038/ng0797-270, ISSN 1061-4036, pages 270 - 276, XP002926493 | |
| OPPOSITION | - Perera Lalith, Darden Thomas, Pedersen Lee, "Modeling Human Zymogen Factor IX", Thrombosis and Haemostasis, Schattauer GmbH, DE, DE , (20010401), vol. 85, no. 04, doi:10.1055/s-0037-1615639, ISSN 0340-6245, pages 596 - 603, XP093133909 | |
| OPPOSITION | - GAO GUANG-PING, ET AL, "Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20020903), vol. 99, no. 18, doi:10.1073/PNAS.182412299, ISSN 0027-8424, pages 11854 - 11859, XP002589975 | |
| OPPOSITION | - R A McGraw, L M Davis, C M Noyes, R L Lundblad, H R Roberts, J B Graham, and D W Stafford, "Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19850501), vol. 82, no. 9, doi:10.1073/pnas.82.9.2847, ISSN 0027-8424, pages 2847 - 2851, XP008146066 | |
| OPPOSITION | - BRANDSTETTER HANS ET AL, "X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19950101), vol. 92, no. 21, doi:10.1073/pnas.92.21.9796, ISSN 0027-8424, pages 9796 - 9800, XP002199692 | |
| OPPOSITION | - WANG L, ET AL, "A factor IX-deficient mouse model for hemophilia B gene therapy", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19971001), vol. 94, no. 21, doi:10.1073/pnas.94.21.11563, ISSN 0027-8424, pages 11563 - 11566, XP002278403 | |
| OPPOSITION | - KURACHI SUMIKO, ET AL, "Role of intron I in expression of the human factor IX gene", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19950310), vol. 270, no. 10, doi:10.1074/jbc.270.16.9289, ISSN 0021-9258, pages 5276 - 5281, XP002297652 | |
| OPPOSITION | - CHANG JINLI ET AL, "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19980515), vol. 273, no. 20, doi:10.1074/jbc.273.20.12089, ISSN 0021-9258, pages 12089 - 12094, XP002199691 | |
| OPPOSITION | - MATHUR A, BAJAJ S PAUL, "Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19990625), vol. 274, no. 26, doi:10.1074/jbc.274.26.18477, ISSN 0021-9258, pages 18477 - 18486, XP002555906 | |
| OPPOSITION | - Bajaj S. Paul, Schmidt Amy E., Mathur Akash, Padmanabhan K., Zhong Degang, Mastri Maria, Fay Philip J., "Factor IXa:Factor VIIIa Interaction", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20010501), vol. 276, no. 19, doi:10.1074/jbc.M011680200, ISSN 0021-9258, pages 16302 - 16309, XP093133908 | |
| OPPOSITION | - Kofler Stefan, Ackaert Chloé, Samonig Martin, Asam Claudia, Briza Peter, Horejs-Hoeck Jutta, Cabrele Chiara, Ferreira Fatima, Duschl Albert, Huber Christian, Brandstetter Hans, "Stabilization of the Dimeric Birch Pollen Allergen Bet v 1 Impacts Its Immunological Properties", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20140103), vol. 289, no. 1, doi:10.1074/jbc.M113.518795, ISSN 0021-9258, pages 540 - 551, XP055938820 | |
| OPPOSITION | - Wang Lili, Figueredo Joanita, Calcedo Roberto, Lin Jianping, Wilson James M., "Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic Targets", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (20070301), vol. 18, no. 3, doi:10.1089/hum.2007.001, ISSN 1043-0342, pages 185 - 194, XP093133900 | |
| OPPOSITION | - Brunetti-Pierri Nicola et al, "Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (20090501), vol. 20, no. 5, doi:10.1089/hum.2008.084, ISSN 1043-0342, pages 479 - 485, XP093208035 | |
| OPPOSITION | - Hopfner K.-P., Brandstetter Hans, Karcher Annette, Kopetzki Erhard, Huber Robert, Engh Richard A, Bode Wolfram, "Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants", THE EMBO JOURNAL, (19971115), vol. 16, no. 22, doi:10.1093/emboj/16.22.6626, ISSN 1460-2075, pages 6626 - 6635, XP093133886 | |
| OPPOSITION | - GIANNELLI F ET AL, "HEMOPHILIA B DATABASE OF POINT MUTATIONS AND SHORT ADDITIONS AND DELETIONS", Nucleic Acids Research, Oxford University Press, GB, GB , (19900101), vol. 18, no. 14, doi:10.1093/nar/18.14.4053, ISSN 0305-1048, pages 4053 - 4060, XP002774525 | |
| OPPOSITION | - F. Giannelli et al., "Haemophilia B (sixth edition): a database of point mutations and short additions and deletions", Nucleic acids research, (199612), vol. 24, doi:10.1093/nar/24.1.103, page 1, XP055036054 | |
| OPPOSITION | - Hough C., Lillicrap D., "Gene therapy for hemophilia: an imperative to succeed : Gene therapy for hemophilia", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, GB , (20050601), vol. 3, no. 6, doi:10.1111/j.1538-7836.2005.01401.x, ISSN 1538-7933, pages 1195 - 1205, XP055788976 | |
| OPPOSITION | - Pierce G.F. et al, "Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment", Journal of thrombosis and haemostasis, John Wiley & Sons, (20070501), vol. 5, no. 5, doi:10.1111/j.1538-7836.2007.02410.x, ISSN 1538-7836, pages 901 - 906, XP093208037 | |
| OPPOSITION | - BOWIE J U, ET AL., "DECIPHERING THE MESSAGE IN PROTEIN SEQUENCES: TOLERANCE TO AMINO ACID SUBSTITUTIONS", Science, American Association for the Advancement of Science, US, US , (19900301), vol. 247, doi:10.1126/science.2315699, ISSN 0036-8075, pages 1306 - 1310, XP002939052 | |
| OPPOSITION | - Federico Mingozzi, Yi-Lin Liu, Eric Dobrzynski, Antje Kaufhold, Jian Hua Liu, Yuqin Wang, Valder R. Arruda, Katherine A. High, Roland W. Herzog, "Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer", The Journal of Clinical Investigation, B M J Group, (20030501), vol. 111, no. 9, doi:10.1172/JCI16887, pages 1347 - 1356, XP055738053 | |
| OPPOSITION | - Manno C. S., Chew A. J., Hutchison S., Larson P. J., Herzog R. W., Arruda V. R., Tai S. J., Ragni M. V., Thompson A., Ozelo M., Couto L. B., Leonard D. G. B., Johnson F. A., Mcclelland A., Scallan C., Skarsgard E., Flake A. W., Kay M. A., High K. A., Glader B., "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B", Blood, American Society of Hematology, US, US , (20030415), vol. 101, no. 8, doi:10.1182/blood-2002-10-3296, ISSN 0006-4971, pages 2963 - 2972, XP093133892 | |
| OPPOSITION | - SABATINO DENISE E ET AL, "Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene", Blood, American Society of Hematology, US, US , (20041101), vol. 104, no. 9, doi:10.1182/blood-2004-03-1028, ISSN 0006-4971, pages 2767 - 2774, XP002555908 | |
| OPPOSITION | - Joerg Schuettrumpf, Et Al., "Factor IX variants improve gene therapy efficacy for hemophilia B", Blood, (20050315), vol. 105, no. 6, doi:10.1182/blood-2004-08-2990, pages 2316 - 2323, XP055542043 | |
| OPPOSITION | - J. D. Finn, T. C. Nichols, N. Svoronos, E. P. Merricks, D. A. Bellenger, S. Zhou, P. Simioni, K. A. High, V. R. Arruda, "The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy", Blood, American Society of Hematology, US, US , (20121129), vol. 120, no. 23, doi:10.1182/blood-2012-06-440123, ISSN 0006-4971, pages 4521 - 4523, XP055394019 | |
| OPPOSITION | - Pipe Steven, Paul Van Der Valk , Peter Verhamme, Peter Kampmann, Frank W.G. Leebeek, Michiel Coppens, Karina Meijer, Priyanka Raheja, Nigel S. Key, Nathan Visweshwar, Guy Young, Richard S. Lemons, Robert Klamroth, Wolfgang Miesbach, Jan Astermark, Niamh O'connell, Rashid Saeed Kazmi, Nicholas Galante, Sandra Lequellec, Paul Monahan, Cedric R. Herman, "Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B", Blood, (20231102), vol. 142, no. suppl. 1, doi:10.1182/blood-2023-187624, page 1055, XP093182327 | |
| OPPOSITION | - Samelson-Jones Benjamin J., Finn Jonathan D., Raffini Leslie J., Merricks Elizabeth P., Camire Rodney M., Nichols Timothy C., Arruda Valder R., "Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants", Blood Advances, (20210309), vol. 5, no. 5, doi:10.1182/bloodadvances.2019000405, ISSN 2473-9529, pages 1324 - 1332, XP093107954 | |
| OPPOSITION | - ROTH DAVID A ET AL, "Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates", Blood, American Society of Hematology, US, US , (20011215), vol. 98, no. 13, doi:10.1182/blood.V98.13.3600, ISSN 0006-4971, pages 3600 - 3606, XP002442457 | |
| OPPOSITION | - MOUNT J D , ET AL, "Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy", Blood, American Society of Hematology, US, US , (20020415), vol. 99, no. 8, doi:10.1182/blood.V99.8.2670, ISSN 0006-4971, pages 2670 - 2676, XP002312777 | |
| OPPOSITION | - Brownlee G. G., "The Molecular Genetics of Haemophilia A and B", Journal of cell science, Company of Biologists Limited, Cambridge, Cambridge , (19860101), vol. 1986, no. Supplement_4, doi:10.1242/jcs.1986.Supplement_4.24, ISSN 0021-9533, pages 445 - 458, XP093133902 | |
| OPPOSITION | - Bezemer I. D., Arellano A. R., Tong C. H., Rowland C. M., Ireland H. A., Bauer K. A., Catanese J., Reitsma P. H., Doggen C. J.M., Devlin J. J., Rosendaal F. R., Bare L. A., "F9 Malmo, factor IX and deep vein thrombosis", Haematologica, Fondazione Ferrata Storti, IT, IT , (20090501), vol. 94, no. 5, doi:10.3324/haematol.2008.003020, ISSN 0390-6078, pages 693 - 699, XP093133910 | |
| OTHER | - Lubert STRYER, Biochemistry 4th Edition, (1995), pages 19-21, 140-151, 421-422, 432 - 434 | - |
| OTHER | - Marks Lara, "Gene therapy ", what is biotechnology?, (20180101), pages 1 - 14, what is biotechnology?, URL: https://www.whatisbiotechnology.org/index.php/science/summary/gene-therapy/, (20220705), XP055938784 | - |
| OTHER | - Stefan Kofler 1, Claudia Asam, Ulrich Eckhard, Michael Wallner, Fátima Ferreira, Hans Brandstetter, "Crystallographically mapped ligand binding differs in high and low IgE binding isoforms of birch pollen allergen bet v 1", J Mol Biol ., (20120907), vol. 422, no. 1, pages 109 - 123, XP055938808 | - |
| OTHER | - POMMIÉ CHRISTELLE ET AL, "IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties.", JOURNAL OF MOLECULAR RECOGNITION., HEYDEN & SON LTD., LONDON., GB, GB , (20040101), vol. 17, no. 1, doi:10.1002/JMR.647, ISSN 0952-3499, pages 17 - 32, XP002516734 | |
| OTHER | - Kuzmin Dmitry A.; Shutova Maria V.; Johnston Natalie R.; Smith Owen P.; Fedorin Vasily V.; Kukushkin Yury S.; van der Loo Johannes C.M.; Johnstone Elaine C., "The clinical landscape for AAV gene therapies", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (19000101), vol. 20, no. 3, doi:10.1038/d41573-021-00017-7, ISSN 1474-1776, pages 173 - 174, XP037400659 | |
| OTHER | - MATHUR AKASH, BAJASJ S.P., "Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19990625), vol. 274, no. 26, doi:10.1074/jbc.274.26.18477, ISSN 0021-9258, pages 18477 - 18486, XP002523381 | |
| OTHER | - Kofler Stefan, Ackaert Chloé, Samonig Martin, Asam Claudia, Briza Peter, Horejs-Hoeck Jutta, Cabrele Chiara, Ferreira Fatima, Duschl Albert, Huber Christian, Brandstetter Hans, "Stabilization of the Dimeric Birch Pollen Allergen Bet v 1 Impacts Its Immunological Properties", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20140103), vol. 289, no. 1, doi:10.1074/jbc.M113.518795, ISSN 0021-9258, pages 540 - 551, XP055938820 | |
| SEARCH | - ANSON D S ET AL, "THE GENE STRUCTURE OF HUMAN ANTI-HAEMOPHILIC FACTOR IX", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (19840101), vol. 3, no. 5, ISSN 0261-4189, pages 1053 - 1060, XP000872222 [I] 1-2,5-8 * page 1054; figure 2 * | - |
| SEARCH | [ ] - JONATHAN D. FINN ET AL, "Abstract 694 - FIX-R338L (FIX Padua) as a Successful Alternative for the Treatment of Canine Severe Hemophilia B", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 22, ISSN 0006-4971, (20091203), (20101005), XP002774527 [ ] * the whole document * | - |
| SEARCH | - yoshitake s. et al, "Human coagulation factor IX gene, complete cds", DATABASE EMBL, (19860128), Database accession no. K02402, URL: EBI, XP002774526 [A] 6-8 * the whole document * | - |
| SEARCH | - LU H ET AL, "Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX", SCIENCE IN CHINA. SERIE C: LIFE SCIENCE, GORDON AND BREACH, AMSTERDAM, NL, (20011201), vol. 44, no. 6, doi:10.1007/BF02879352, ISSN 1006-9305, pages 585 - 592, XP009114604 [I] 11-25 * the whole document * | |
| SEARCH | - YAN JING-BIN ET AL, "Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.", BIOCHEMICAL GENETICS OCT 2006, (200610), vol. 44, no. 7-8, ISSN 0006-2928, pages 349 - 360, XP019447249 [I] 1-2,5-6,8-25 * the whole document * | |
| SEARCH | [ ] - SIMIONI PAOLO ET AL, "X-linked thrombophilia with a mutant factor IX (factor IX Padua).", THE NEW ENGLAND JOURNAL OF MEDICINE 22 OCT 2009, (20091022), vol. 361, no. 17, ISSN 1533-4406, pages 1671 - 1675, XP002555909 [ ] * the whole document * | |
| SEARCH | - KURACHI S ET AL, "ROLE OF INTRON I IN EXPRESSION OF THE HUMAN FACTOR IX GENE", JOURNAL OF BIOLOGICAL CHEMISTRY,, (19950310), vol. 270, no. 10, doi:10.1074/JBC.270.16.9289, ISSN 0021-9258, pages 5276 - 5281, XP002055415 [A] 6-8 * the whole document * | |
| SEARCH | - CHANG JINLI ET AL, "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, (19980515), vol. 273, no. 20, ISSN 0021-9258, pages 12089 - 12094, XP002199691 [DA] 1-2,5-6,8-13,15-18,21-25 * the whole document * | |
| SEARCH | - GIANNELLI F ET AL, "HEMOPHILIA B DATABASE OF POINT MUTATIONS AND SHORT ADDITIONS AND DELETIONS", NUCLEIC ACIDS RESEARCH,, (19900101), vol. 18, no. 14, doi:10.1093/NAR/18.14.4053, ISSN 0305-1048, pages 4053 - 4060, XP002774525 [A] 6-8 * the whole document * | |
| SEARCH | - SABATINO DENISE E ET AL, "Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene", BLOOD, (20041101), vol. 104, no. 9, ISSN 0006-4971, pages 2767 - 2774, XP002555908 [A] 1-2,5-6,8-13,18,21-25 * the whole document * | |
| SEARCH | - SCHUETTRUMPF JOERG ET AL, "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, (20050315), vol. 105, no. 6, ISSN 0006-4971, pages 2316 - 2323, XP002555907 [I] 18,21-25 * the whole document * | |
